Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and maintains $40 price target.
Stocks · News reference
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to survive another
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Artiva Biotherapeutics Presents Updated Clinical, Safety And Translational Data For AlloNK In Combination With Rituximab At 17th ISSjD 2026 In Paris
8-K filing — Artiva Biotherapeutics, Inc. (ARTV)
Filed: 2026-09-11 AccNo: 0001193125-26-389308 Size: 620 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits
Artiva Biotherapeutics Says It Is Initiating Phase 3 Trial Of AlloNK Plus Rituximab In About 150 Refractory RA Patients In H2 2026; Expects Updated Phase 2a Data From At Least 20 RA Patients In H2 2026
Cellectar Says Iopofosine I 131 Showed 87.5% Response Rate In 24-Patient Post-BTK Inhibitor Subgroup Of Phase 2b Waldenström Macroglobulinemia Trial
Cellectar Biosciences Reports 79.2% Major Response Rate For Iopofosine I 131 In Phase 2 Subset Of Waldenström Macroglobulinemia Patients After BTK Inhibitors